Clinical Trial

Low-grade UTUC Treated With Nadofaragene Firadenovec Administered to Renal Pelvis

Study acronym: LUNAR
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The primary purpose of this trial is to evaluate the safety \& tolerability of Nadofaragene Firadenovec in subjects with LG-UTUC. To help with this evaluation, a safety lead-in period will be conducted for the first 6 subjects. Complete response is at 3 or 6 months defined as absence of any UTUC in the renal pelvis.
Protocol Amendment History 10 amendments
This ClinicalTrials.gov record has been amended 10 times since 2024-10-30; most recent amendment 2026-05-06.
Status change: Not Yet Recruiting → Recruiting 2025-06-16
Trial Details
NCT Number NCT06668493
Lead Sponsor Ferring Pharmaceuticals
Conditions Low-grade Upper Tract Urothelial Carcinoma
Enrollment 20 participants
Start Date 2025-06-12
Primary Completion 2029-11-30 (estimated)
Study Completion 2029-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-05-08